Learn More about Lumida ETF
Powered by LumidaWealth.com
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
  • Home
  • EarningsNEW
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us
No Result
View All Result
Lumida News
No Result
View All Result
  • Lumida Wealth
  • Lumida Ledger
  • LUMIDA ETF
  • About Us
Home Lifestyle Health and Longevity

One-Third of Americans Now Use AI for Health Advice — and Many Are Skipping the Doctor

by Team Lumida
March 31, 2026
in Health and Longevity
Reading Time: 4 mins read
A A
0
One-Third of Americans Now Use AI for Health Advice — and Many Are Skipping the Doctor
Share on TelegramShare on TwitterShare on FacebookShare on LinkedinShare on Whatsapp

Key Takeaways

  • Roughly 1 in 3 U.S. adults have used AI to find health information, with nearly 30% seeking physical health advice and 1 in 6 turning to AI for mental health questions — making AI as common a health resource as social media, according to a new KFF poll of more than 1,300 adults.
  • More than 40% of health AI users have uploaded personal medical data — including test results and doctor’s notes — into AI tools, even as more than three-quarters of all adults say they are very or somewhat concerned about health data privacy.
  • About 1 in 5 AI health users cited inability to get an appointment or lack of a provider as a major driver — signaling that AI is increasingly filling access-to-care gaps rather than simply supplementing routine medical consultations.
  • Younger adults and low-income individuals are most likely to use AI for health questions and least likely to follow up with a provider afterward — raising concerns that AI may be widening rather than bridging healthcare equity gaps.

What Happened?

A new poll from KFF, the nonpartisan health policy research organization, finds that approximately one-third of U.S. adults have used AI tools to seek health information — a level of adoption that now rivals social media as a source of health guidance. The survey, conducted among more than 1,300 adults, found that 29% had used AI for physical health information in the past year and 1 in 6 had used it for mental health queries. The most cited reason for using AI was the desire for quick health advice, followed by researching information before a doctor’s visit. However, a significant minority — about 1 in 5 users — said they turned to AI specifically because they lacked a provider or couldn’t secure an appointment, underlining AI’s growing role as a substitute for, not just a supplement to, professional medical care. The poll also found that about 6 in 10 adults who used AI for physical health advice subsequently saw a doctor, and 4 in 10 sought a mental health professional — but younger adults were considerably less likely to make that follow-up visit.

Why It Matters?

For investors in healthcare AI and digital health, the KFF poll provides some of the most concrete market sizing data yet for the consumer health AI category. OpenAI, Microsoft, and Amazon have all launched health-specific AI tools in recent months, betting on exactly this kind of mass adoption. The 40%-plus rate of personal medical data uploads into AI tools is particularly significant: it suggests consumers are already treating these platforms as quasi-medical record repositories, creating both a competitive moat for the platforms that capture this data and a serious regulatory risk as the FTC, HHS, and state attorneys general scrutinize AI health data practices. The finding that younger, lower-income users are most likely to use AI as a primary — not supplementary — healthcare resource raises important equity and liability questions. If AI health tools give misleading or incomplete advice to populations that are least likely to follow up with a clinician, the public health consequences could be significant and the legal exposure for AI companies could be material.

What’s Next?

The health AI market is accelerating on multiple fronts simultaneously. OpenAI’s health-specific ChatGPT launched in January, Microsoft’s dedicated health AI chatbot followed in March, and Amazon expanded its health-focused AI assistant the same month — suggesting the competitive intensity will only increase. Regulatory clarity, however, is lagging: the FDA has begun scrutinizing AI clinical decision support tools but has not yet established clear standards for consumer-facing health AI. The data privacy concern flagged by KFF — more than 75% of adults worried about personal health data in AI systems — is a regulatory flashpoint that could trigger HIPAA-adjacent legislation if a major data breach occurs. For investors evaluating healthcare AI plays, the key metrics to watch are not just user numbers but follow-up care conversion rates, data upload penetration, and whether platforms can monetize the health data they’re collecting without triggering a regulatory or reputational crisis.


Source: https://www.healthcaredive.com/news/kff-poll-ai-health-information-adults/744217/

Previous Post

The Iran War’s Invisible Casualty: A Helium Crisis That Could Cripple AI Chips and MRI Scanners

Next Post

Wall Street Just Wrapped Its Worst Quarter in Four Years — and Investors Are Bracing for Worse

Recommended For You

Melatonin: What Mayo Clinic Says About Its Side Effects, Safety, and Best Uses

by Team Lumida
5 days ago
Melatonin: What Mayo Clinic Says About Its Side Effects, Safety, and Best Uses

Melatonin is generally safe for short-term use and non-habit-forming, but it carries real side effects and drug interactions that most users overlook — Mayo Clinic breaks down what...

Read more

How Much Muscle Should You Have — and What Happens When You Lose It?

by Team Lumida
6 days ago
diagram

Muscle mass averages, why they matter for long-term health, and what the science says about measuring and building skeletal muscle across every age group.

Read more

AI Scribes Save Clinicians 13–16 Minutes a Day — and Boost Visit Volume by 1.7%, Study Finds

by Team Lumida
1 week ago
AI Investment Boom: How Tech Giants Are Leading the Charge

The largest study of AI scribe adoption to date — 8,500+ clinicians across five academic medical centers — found the tools cut EHR time by 3% and documentation...

Read more

America’s Fertility Rate Just Hit a Record Low — and the Numbers Are Getting Harder to Ignore

by Team Lumida
1 week ago
America’s Fertility Rate Just Hit a Record Low — and the Numbers Are Getting Harder to Ignore

The U.S. general fertility rate fell to 53.1 births per 1,000 women in 2025 — a record low — while the total fertility rate dropped to 1.57, well...

Read more

Healthcare Roundup: Medicare Advantage Gets a $13B Boost, Drug Tariffs Hit 100%, and Wegovy Goes Discount

by Team Lumida
2 weeks ago
person sitting while using laptop computer and green stethoscope near

A packed week in healthcare: Medicare Advantage rates came in at a better-than-expected 2.48% increase, Trump unveiled 100% tariffs on some brand-name drugs, Gilead and Neurocrine spent $8B...

Read more

Why Americans Pay More for Healthcare Than Anyone Else in the World

by Team Lumida
2 weeks ago
doctor holding red stethoscope

A new WSJ analysis breaks down the structural forces behind America's sky-high healthcare costs — from monopoly hospitals and unregulated drug prices to administrative bloat and physician salaries...

Read more

Genetic Tests Come Under Federal Scrutiny as Trump Administration Targets Lab Fraud

by Team Lumida
2 weeks ago
Supreme Court Signals It Will Strike Down Trump’s Birthright Citizenship Order

The CMS has opened a public comment period on how to curb fraudulent genetic testing billing — a billion-dollar problem involving unnecessary tests marketed directly to consumers and...

Read more

94% of Physicians Have Adopted or Want AI — But Accuracy Concerns Remain the Top Barrier

by Team Lumida
3 weeks ago
a man holding a ball in his right hand

A Doximity survey of more than 3,000 physicians finds that AI adoption in clinical practice has surged from 47% to 63% in under a year — but more...

Read more

Up to 10 Million Americans Could Lose Medicaid by 2028 Under New Work Requirements

by Team Lumida
3 weeks ago

A new Urban Institute and Robert Wood Johnson Foundation analysis finds that 5 to 10 million people could be disenrolled from Medicaid in 2028 due to work requirements...

Read more

The Weight Loss Drug Race: What’s Available Now and What’s Coming Next

by Team Lumida
3 weeks ago
The Weight Loss Drug Race: What’s Available Now and What’s Coming Next

The obesity drug market is set for a major expansion, with Eli Lilly's once-daily pill targeting April FDA approval, Novo Nordisk launching a high-dose shot, and six additional...

Read more
Next Post
AI Job-Loss Panic Is Running Ahead of the Data, Says Bloomberg Opinion

Wall Street Just Wrapped Its Worst Quarter in Four Years — and Investors Are Bracing for Worse

McCormick to Buy Unilever’s $15.7B Food Empire in a Deal That Reshapes the Global Pantry

McCormick to Buy Unilever's $15.7B Food Empire in a Deal That Reshapes the Global Pantry

Related News

UPS to Cut 20,000 Jobs and Close 73 Facilities After Amazon Breakup

UPS to Cut 20,000 Jobs and Close 73 Facilities After Amazon Breakup

April 30, 2025

TSMC Edges Towards $1 Trillion Valuation Amid AI Boom and Price Hikes

August 4, 2025
group of people using laptop computer

U.S. Productivity Surge: AI, Innovation, and Post-Pandemic Adaptations Drive Economic Efficiency

January 3, 2025

Subscribe to Lumida Ledger

Browse by Category

  • Lifestyle
    • Family Office
    • Health and Longevity
    • Next Gen Wealth
    • Trust, Tax, and Estate
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Latest
    • Macro
    • Markets
    • Real Estate
  • Research
    • Trackers
  • Themes
    • Aging & Longevity
    • AI
    • Biotech
    • CRE
    • Cybersecurity
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
    • Software
Facebook Twitter Instagram Youtube TikTok LinkedIn
Lumida News

Premium insights to help you invest beyond the ordinary. Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser

CATEGORIES

  • Aging & Longevity
  • AI
  • Alt Assets
  • Biotech
  • CRE
  • Crypto
  • Cybersecurity
  • Digital Assets
  • Equities
  • Family Office
  • Health and Longevity
  • Latest
  • Legacy Brands
  • Lifestyle
  • Macro
  • Markets
  • News
  • Next Gen Wealth
  • Nuclear Renaissance
  • Private Credit
  • Real Estate
  • Software
  • Themes
  • Trackers
  • Trust, Tax, and Estate

BROWSE BY TAG

AI AI chips AI demand Amazon Apple Artificial Intelligence Banking Bitcoin China Commercial Real Estate CPI Crypto Donald Trump EARNINGS ELON MUSK ETF Ethereum Federal Reserve financial services generative AI Goldman Sachs Google India Inflation Interest Rates Investment Strategy Japan Jerome Powell JPMorgan Markets Meta Microsoft Nasdaq Nvidia OpenAI private equity S&P 500 SEC Semiconductor stock market Tech Stocks tesla Trump Wells Fargo Whale Watch

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018

No Result
View All Result
  • Home
  • Earnings
  • News
    • Alt Assets
    • Crypto
    • Equities
    • Macro
    • Markets
    • Real Estate
  • Lifestyle
    • Family Office
    • Health and Longevity
  • Themes
    • Aging & Longevity
    • AI
    • CRE
    • Digital Assets
    • Legacy Brands
    • Nuclear Renaissance
    • Private Credit
  • About Us

© 2025 Lumida Wealth Management LLC is an SEC registered investment adviser. Privacy Policy. Cookies Policy.
Disclaimer Important Information This site is for informational purposes only. Information presented on this site does not constitute as investment advice.

Lumida Wealth Management LLC (‘Lumida”) is an SEC registered investment adviser. SEC registration does not constitute an endorsement of the firm by the Commission nor does it indicate that the adviser has attained a particular level of skill or ability.

Lumida's website (referred to herein as the "Website") is limited to the dissemination of general information pertaining to its advisory services, together with access to additional investment-related information, publications, and links. Accordingly, the publication of the Website on the Internet should not be construed by any client and/or prospective client Lumida’s solicitation to effect, or attempt to effect transactions in securities, or the rendering of personalized investment advice for compensation, over the Internet.

Any subsequent, direct communication by Lumida with a prospective client will be conducted by a representative that is either registered or qualifies for an exemption or exclusion from registration in the state where the prospective client resides.

‍Lead Capture Forms: By submitting your contact information in the forms on this site, you are not obligated to invest in Lumida's product or services.
‍Address: Lumida Wealth Management, 25 W 39th Street Suite 700, New York, NY 10018